Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verrica Pharmaceuticals Inc VRCA

Healthcare
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential... see more

Recent & Breaking News (NDAQ:VRCA)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

GlobeNewswire August 15, 2020

VRCA Shareholder Update: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

ACCESSWIRE IA August 13, 2020

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GEO Group, Wirecard, J2 Global, and Verrica Pharmaceuticals and Encourages Investors to Contact the Firm

GlobeNewswire August 12, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

ACCESSWIRE IA August 12, 2020

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

PR Newswire August 12, 2020

DEADLINE ALERT for VRCA, DB, and BAYRY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire August 12, 2020

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA August 11, 2020

Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications

GlobeNewswire August 11, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

GlobeNewswire August 10, 2020

DEADLINE ALERT for GEO, WCAGY, JCOM, VRCA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire August 7, 2020

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wirecard, J2 Global, Verrica Pharmaceuticals, and Deutsche Bank and Encourages Investors to Contact the Firm

GlobeNewswire August 5, 2020

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

GlobeNewswire August 5, 2020

Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results

GlobeNewswire August 5, 2020

Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan

GlobeNewswire August 5, 2020

FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA August 4, 2020

Investor Alert: Kaplan Fox Investigates Verrica Pharmaceuticals Inc. For Potential Securities Fraud

PR Newswire August 4, 2020

VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

ACCESSWIRE IA August 4, 2020

DEADLINE ALERT for VRCA, DB, and BAYRY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire August 4, 2020

DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA August 3, 2020

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

PR Newswire August 3, 2020